An old anti-seizure drug might also work to reduce apnea episodes, recent trial data has shown.
RFK Jr. plans to reverse a sweeping compounding ban of certain peptides issued by the FDA in late 2023.
People taking DMT tended to experience significant relief from their depression for up to three months, the researchers found.
In Phase II data released this week, people taking a monthly dose of PF’3944 continued to lose more weight than those on a placebo.
An experimental injection could restore the youthfulness of eggs taken from older women.
Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.
The topical medication, called Clascoterone, could represent the first truly novel drug for male pattern baldness seen in about 30 years.
An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.
University of Maryland researchers are developing a vaccine that targets the dangerous foodborne bug, Salmonella.
New research in mice suggests that stevia can boost the potency of minoxidil, the active ingredient in popular hair loss treatments like Rogaine.
Vertanical has already filed for approval of its cannabis-based drug, named VER-01, in Europe.
In a trial of people with early Huntington's, the newly developed therapy slowed the progression of symptoms by 75%.
In a phase I trial, SNT-6302 showed early signs of remodeling the skin within people's scar tissue.
New Phase I trial data finds that people who responded to ELI-002 survived longer and stayed cancer-free longer than usual.
YourChoice Therapeutics is already testing its drug in a larger Phase II trial.
In early animal tests, the experimental TDN triggered weight loss without nausea or vomiting.
The FDA will decide whether to approve Replimune's RP1 virus for treating advanced melanoma later this month.
Several larger trials of ambroxol for Parkinson's are already underway.
People taking Amgen's MariTide lost up to 20% of their body weight in a Phase II trial.
Will more technology make America healthier?
